Janux Therapeutics JANX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.83M-1.0% | $52.33M+8.2% | $48.39M-7.7% | $52.45M-28.9% | $73.74M-82.9% | ||
| $904.56M-1.1% | $914.23M-2.8% | $940.6M-0.3% | $943.57M+0.3% | $940.4M+58.2% | ||
| —— | —— | —— | —— | —— | ||
| $1B+2.7% | $975.89M-2.2% | $998.09M-0.7% | $1.01B-1.7% | $1.02B-1.0% | ||
| $3.55M-7.9% | $3.85M-10.7% | $4.31M-8.0% | $4.69M-5.2% | $4.95M+1.7% | ||
| $1.03B+2.7% | $1B-2.3% | $1.02B-0.7% | $1.03B-1.8% | $1.05B-1.0% | ||
| $15.22M+7.2% | $14.19M+7.1% | $13.25M+7.6% | $12.32M+22.0% | $10.09M+1.0% | ||
| —— | —— | —— | —— | —— | ||
| $58.92M+136% | $25M-10.2% | $27.83M+30.2% | $21.38M+22.2% | $17.5M+0.2% | ||
| $86.69M+93.8% | $44.74M-7.2% | $48.21M+15.6% | $41.7M+8.9% | $38.3M-1.1% | ||
| $60K0.0% | $60K0.0% | $60K+1.7% | $59K0.0% | $59K0.0% | ||
| -$375.74M-6.9% | -$351.38M-10.0% | -$319.44M-8.2% | -$295.12M-13.0% | -$261.27M-9.9% | ||
| $941.54M-1.6% | $956.82M-2.0% | $976.56M-1.4% | $990.52M-2.2% | $1.01B-1.0% | ||
| $1.03B+2.7% | $1B-2.3% | $1.02B-0.7% | $1.03B-1.8% | $1.05B-1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Janux Therapeutics's total assets?
- Janux Therapeutics (JANX) holds $1.0B in total assets, down 2.1% year over year.
- How much debt does Janux Therapeutics have?
- Janux Therapeutics carries $21.6M in total debt against $941.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Janux Therapeutics have?
- Janux Therapeutics holds $51.8M in cash and equivalents.
- Can Janux Therapeutics cover its short-term obligations?
- Its current ratio is 17.01 — current assets exceed current liabilities.
- Where does Janux Therapeutics's balance sheet data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
